Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL22 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | BL22 immunotoxin |
| Name | Type | Description |
|---|---|---|
| BL22 | DRUG | Dosing via IV on Days 1,3, and 5. |
DISEASE CHARACTERISTICS: * Histologically confirmed hairy cell leukemia * CD22-positive disease by fluorescence-activated cell sorting with anti-CD22 antibody * Meets at least 1 of the following indications for treatment: * Absolute neutrophil count less than 1,000/mm\^3 * Hemoglobin less than...
Top 20 of 63 competitors
BL22 is an investigational small molecule being studied for the treatment of leukemia, specifically in patients previously treated with cladribine for hairy cell leukemia. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
BL22 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy for leukemia.
BL22 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to determine its safety and effectiveness for treating leukemia.
BL22 has been studied in one completed Phase 2 clinical trial with the identifier NCT00074048. This trial evaluated BL22 in patients previously treated with cladribine for hairy cell leukemia and enrolled 36 participants in the United States.
BL22 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed clinical trial for BL22 was an uncontrolled study, and further research would be needed to establish its safety and efficacy for regulatory approval.